MilliporeSigma to invest over € 300 million in new bioproduction site in Korea

346

0 comment

Staff at TrialSite | Quality Journalism

Mar. 24, 2024, 8:00 p.m.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, announced an investment of more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.

The new site is the largest investment by the company’s Life Science business sector in Asia-Pacific to date and is expected to create approximately 300 additional jobs by the end of 2028.

Quality journalism costs money to produce.

Free access provides up to 10 articles

Subscription options start at $5 per month
which is less than a Starbucks coffee!

Peter Gabriel, MD

"Publishing on TrialSite helped me secure a $20m research grant for my work."

Jona Savinda

"TrialSiteNews is my daily read for what is happening in the industry."